DUBLIN--(BUSINESS WIRE)--The "Diabetic Gastroparesis - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.
Diabetic Gastroparesis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Diabetic Gastroparesis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Diabetic Gastroparesis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Gastroparesis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 3, 1 and 2 respectively.
Diabetic Gastroparesis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Diabetic Gastroparesis - Overview
- Diabetic Gastroparesis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Diabetic Gastroparesis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Diabetic Gastroparesis - Companies Involved in Therapeutics Development
- Allergan Plc
- Cempra Inc
- Evoke Pharma Inc
- GlaxoSmithKline Plc
- Johnson & Johnson
- Theravance Biopharma Inc
For more information about this report visit https://www.researchandmarkets.com/research/vsxg4h/diabetic